Evidence map›Paper›PMID 31205916›Full record

ArticleAnnals of translational medicine2019

Long non-coding RNA IQCJ-SCHIP1 antisense RNA 1 is downregulated in colorectal cancer and inhibits cell proliferation.

Jia Zhang, Zehua Bian, Guoying Jin, Yuhang Liu, Min Li, Surui Yao, Jing Zhao, Yuyang Feng, Xue Wang, Yuan Yin and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Annals of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Jia ZhangWuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi 214062, China.
Zehua BianWuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi 214062, China.
Guoying JinWuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi 214062, China.
Yuhang LiuWuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi 214062, China.
Min LiWuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi 214062, China.
Surui YaoWuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi 214062, China.
Jing ZhaoCancer Epigenetics Program, Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China.
Yuyang FengCancer Epigenetics Program, Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China.
Xue WangCancer Epigenetics Program, Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China.
Yuan YinWuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi 214062, China.
Bojian FeiDepartment of Surgical Oncology, Affiliated Hospital of Jiangnan University, Wuxi 214062, China.
Xiaofeng HanCancer Epigenetics Program, Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China.
Zhaohui HuangWuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi 214062, China.
Wuxi Fourth People's Hospital · CNJiangnan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIQCJ-SCHIP1 antisense RNA 1 (IQCJ-SCHIP1-AS1) was a functional novel long non-coding RNA (lncRNA) revealed by our previous expression profile. In this study, we aim to investigate its clinical relevance and biological significance in colorectal cancer (CRC).

methodsWe measured the expression levels of IQCJ-SCHIP1-AS1 in 86 paired CRC tissues using quantitative RT-PCR assay, and then analyzed its association with patient prognoses. Moreover, gain-of-function and loss-of-function studies were performed to examine the biological functions of IQCJ-SCHIP1-AS1. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and gene set enrichment analysis (GSEA) were used to elucidate potential mechanisms of IQCJ-SCHIP1-AS1 in CRC.

resultsMore than 2-fold decreased expression of IQCJ-SCHIP1-AS1 was found in half of CRC tissues (53.5%, 46/86). IQCJ-SCHIP1-AS1 down-regulation was correlated with poor differentiation (P=0.025), advanced depth of tumor (P=0.022), lymphatic invasion (P=0.010), advanced tumor stage (P=0.006), and poor prognosis (P=0.0027) in CRC patients. The Cox proportional hazards model demonstrated that IQCJ-SCHIP1-AS1 expression was an independent prognostic factor for CRC (HR =0.247, 95% CI: 0.081-0.752, P=0.014). Moreover, knockdown of IQCJ-SCHIP1-AS1 promoted CRC cell proliferation through increasing cell cycle progression and impairing cell apoptosis. Additionally, bioinformatics analysis showed that differential expression genes in IQCJ-SCHIP1-AS1-depleted CRC cells were enriched in the pathways of cell cycle, DNA replication, and p53.

conclusionsOur results demonstrate that IQCJ-SCHIP1-AS1 has an indicative tumor suppressor role and appears to be a potential prognostic factor in CRC for the first time.

Indexed as

biomarkercolorectal cancer (CRC)IQCJ-SCHIP1 antisense RNA 1 (IQCJ-SCHIP1-AS1)Long non-coding RNA (lncRNA)

Identifiers

PMID31205916
PMCPMC6545302
OpenAlexW2936379216

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.